Syngen Biotech Co.,Ltd. (TPEX:8279)

Market Cap	2.90B -17.4%
Revenue (ttm)	2.14B +6.1%
Net Income	271.59M +13.1%
EPS	10.01 +13.1%
Shares Out	27.10M
PE Ratio	10.69
Forward PE	n/a
Dividend	5.00 (4.63%)
Ex-Dividend Date	Jun 26, 2025

Volume	24,233
Average Volume	52,118
Open	108.50
Previous Close	108.00
Day's Range	103.50 - 108.50
52-Week Range	100.00 - 148.00
Beta	0.17
RSI	30.04
Earnings Date	Mar 4, 2026

About Syngen Biotech

Syngen Biotech Co.,Ltd., together with its subsidiaries, engages in the research, development, manufacturing, and sale of microbial pharmaceutical raw materials, biological pesticides, fertilizers and biochemical nutritional products, and preventive medicines in Taiwan, China, and internationally. The company offers dietary supplements; supplement contract manufacturing services in the form of sachets, liquids, tablets, cup package capsules, jellies, aluminum and glass bottles, and gummies; science-based and bio active pharmaceutical ingredient...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1988
• Employees: 247
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 8279

Financial Performance

In 2025, Syngen Biotech's revenue was 2.14 billion, an increase of 6.10% compared to the previous year's 2.01 billion. Earnings were 271.59 million, an increase of 13.07%.